In addition, the gHgL-mRNA vaccine was able to elicit a gHgL-specific CD4+ T-cell response in mice that might have partially contributed to the observed in vivo protection against MHV68 latent infection. The gene discussed is CD4; the disease is disease arising from reactivation of latent virus.